Cadrenal TherapeuticsCVKD
Market Cap: $12.9M
About: Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
Employees: 4
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
8.41% less ownership
Funds ownership: 10.6% [Q1] → 2.19% (-8.41%) [Q2]
10% less funds holding
Funds holding: 10 [Q1] → 9 (-1) [Q2]
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
84% less capital invested
Capital invested by funds: $1.04M [Q1] → $165K (-$870K) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for CVKD.
Financial journalist opinion
Based on 3 articles about CVKD published over the past 30 days